Table 6.

Flow Cytometric Analysis of Selected T-Cell Surface Markers (post-treatment–pretreatment) After Two Treatment Cycles for Selected Patients in Cohort 2 (3 → 1 mg/kg)

Patient	HLA-DR+ (%CD3+CD4+)	HLA-DR+ (%CD3+CD4−)	CD45RO+ (%CD3+CD4+)	CD45RO+ (%CD3+CD4−)	CD4+ CD25+ (%CD3+)	CD25+ (%CD3+CD4+)
15	5.8	−1.7	−1.4	−6.1	−2.4	5.9
17	16.3	−0.8	20.8	9.8	−18.3	28.5
19	6.0	2.0	6.6	5.6	−1.8	−1.2
20	9.2	4.0	4.1	−0.1	−5.7	−9.1
21	6.6	11.5	3.0	5.7	−2.9	−5.1
23	4.7	1.5	0.5	5.7	−0.5	−1.3
24	9.9	−1.9	12.6	−2.9	−4.1	−4.9
25	11.0	5.6	18.9	−6.4	−7.9	−9.8
27	17.9	2.5	9.2	2.0	0.5	−1.3
31	3.9	4.9	1.5	−0.4	−2.9	−8.9
32	15.9	1.6	20.1	3.1	3.5	4.4
33	23.7	−1.0	−2.1	−3.1	−8.4	−14.3
34	2.2	0.4	8.1	0.2	−0.1	−0.3
36	3.0	3.2	2.2	6.6	7.2	8.5
39	13.0	1.0	51.6	27.4	−1.6	−0.3
40	7.1	4.2	3.6	−5.2	3.4	3.0
Mean change	+9.8	+2.3	+10.0	+2.6	−2.6	−4.7
P *	.00001	.015	.009	.222	.092	.047

^*Two-tailed P value using paired t-test.